The story appears on

Page B3

November 25, 2024

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » District » Jiading

Deals signed for 25 biopharma projects

A FORUM on high-end medical industry innovation and a conference on biopharma development were held on October 16 at the Shanghai MedValley in Jiading District.

During the event, the Jiading District Biopharma Industry Innovation Alliance, Ruijin Hospital’s Shanghai Institute of Traumatology and Orthopaedics, and the Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Disease with Integrated Chinese-Western Medicine were launched.

According to Zheng Hong, director of the Ministry of Industry and Information Technology’s International Economic and Technological Cooperation Center, China’s medical equipment enterprises above the designated size generated more than 500 billion yuan (US$69.09 billion) in revenue in 2023, marking 10 consecutive years of rapid growth. United Imaging and Mindray are among the world’s top 100 medical equipment companies.

Agreements were inked on 25 biopharma industry projects, totaling more than 2 billion yuan in investments. Furthermore, three biopharma-related funds joined forces with Jiading-based businesses to promote the expansion of the local biopharma industry.

According to industry analysts, the biopharma sector requires long research and development cycles and significant expenses, whereas a development model that combines capital and innovation might attract businesses by effectively relieving financial burdens during the early stages of projects.

The district’s biopharma sector achieved a total output of 28.54 billion yuan in 2023, and 20.13 billion yuan from January to August this year, according to an annual development report on Jiading’s biopharma industry.

Jiading is now home to 1,500 biopharma enterprises engaged in production, research and services.

Meanwhile, the Jiading Biopharma Shared Laboratory Platform was launched on the same day to advance the clustering and collaborative development of the biopharma industry.

As one of the four key functional platforms in the Shanghai MedValley Innovative Medical Device Industrial Park, it is expected to promote resource sharing, enhance experimental efficiency and drive the industry’s high-quality development.




 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend